New CAR-T therapy aims to keep leukemia in remission

NCT ID NCT07575919

Recruiting now Disease control Sponsor: Liping Dou Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new immune cell therapy (dual-target CD22/CD19 CAR-T cells) as a consolidation treatment for people with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who are in remission. The goal is to see if it is safe and can help prevent the cancer from coming back. About 20 participants will receive the therapy and be followed for 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dual-target CD22/CD19 CAR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could offer a more effective consolidation treatment for B-ALL, potentially lowering relapse rates and improving long-term survival.
What could go wrong: This is an early-phase (Phase 1/2) study with only 20 participants, so results may not apply broadly. Risks include serious side effects like cytokine release syndrome and neurotoxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.